PainReform Licenses a Novel Sustained Release Formulation of Ropivacaine from Encore Therapeutics Inc.  
7/2/2008 9:52:11 AM

TEL AVIV, Israel & CARLSBAD, Calif.--(BUSINESS WIRE)--PainReform and Encore Therapeutics today announced that the two companies have entered into a licensing and development agreement related to Encore Therapeutics’ ETI-211 product for the treatment of post surgical pain. The product, which is administered subdermally using Encore Therapeutics proprietary Phospholipid Gel technology, is currently in pre clinical testing.